GeoVax Labs Files S-1 Amidst Corporate Changes
Ticker: GOVX · Form: S-1 · Filed: Sep 6, 2024 · CIK: 832489
Sentiment: neutral
Topics: S-1, pharmaceuticals, corporate-action
TL;DR
GeoVax Labs filed S-1, showing a 2023 reverse split & Feb '24 pre-funded warrants. Investors watch closely.
AI Summary
GeoVax Labs, Inc. filed an S-1 form on September 6, 2024, detailing its financial status and future plans. The company, incorporated in Delaware, is in the pharmaceutical preparations sector. Key financial events include a reverse stock split in 2023 and the issuance of pre-funded warrants in February 2024.
Why It Matters
This S-1 filing provides crucial insights into GeoVax Labs' financial health and strategic direction, impacting investors and the broader biotechnology market.
Risk Assessment
Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carry risks.
Key Numbers
- 2023 — Reverse Stock Split (A significant corporate action impacting share structure.)
- 2024-02-01 — Pre-funded Warrants (Indicates potential future dilution or capital infusion.)
Key Players & Entities
- GeoVax Labs, Inc. (company) — Filer of the S-1 document
- 0001437749-24-028640 (dollar_amount) — Accession Number for the filing
- 20240906 (dollar_amount) — Filing date
- DE (dollar_amount) — State of incorporation
- 2834 (dollar_amount) — Standard Industrial Classification for Pharmaceutical Preparations
- 2023-01-01 (dollar_amount) — Start date for reverse stock split event
FAQ
What is the primary purpose of this S-1 filing for GeoVax Labs, Inc.?
The S-1 filing is a registration statement filed with the SEC, typically used when a company plans to offer securities to the public, indicating potential capital raising or other significant corporate actions.
When was GeoVax Labs, Inc. incorporated and in which state?
GeoVax Labs, Inc. was incorporated in Delaware (DE).
What industry does GeoVax Labs, Inc. operate in?
GeoVax Labs, Inc. operates in the Pharmaceutical Preparations industry, classified under SIC code 2834.
What significant corporate events are mentioned in the filing timeline?
The filing timeline mentions a reverse stock split in 2023 and the issuance of pre-funded warrants in February 2024.
What is the accession number for this specific SEC filing?
The accession number for this filing is 0001437749-24-028640.
Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2024-09-06 16:03:35
Key Financial Figures
- $0.001 — Shares") of our common stock, par value $0.001 per share (the "Common Stock"), issuabl
- $3.84 — ted sale price for our Common Stock was $3.84 per share. Investing in our securities
- $24.3 m — Network. The direct award to GeoVax of $24.3 million, which may increase to as much as
- $45 m — llion, which may increase to as much as $45 million, will fund the manufacturing of c
- $343 million — ies. BARDA has made a separate award of $343 million from the Project NextGen program to All
- $367 — luation of GEO-CM04S1 is expected to be $367-388 million GEO-CM04S1 – Immunocomprom
- $5.125 — ublic offering price for each Share was $5.125 and the public offering price for each
- $5.12499 — for each Aug 30 Pre-Funded Warrant was $5.12499. The Aug 30 Pre-Funded Warrants have an
- $0.0001 — nded Warrants have an exercise price of $0.0001 per share, are exercisable immediately
- $5.00 — mmon Warrants have an exercise price of $5.00 per share, are immediately exercisable
- $4.6 million — ug 30 Common Warrants, is approximately $4.6 million. The Company intends to use the net pro
- $4.9999 — for each Aug 21 Pre-Funded Warrant was $4.9999. The Aug 21 Pre-Funded Warrants have an
- $7.8 million — ug 21 Common Warrants, is approximately $7.8 million. The Company intends to use the net pro
- $2.86 — offering price for each July Share was $2.86 and the public offering price for each
- $2.85999 — ce for each July Pre-Funded Warrant was $2.85999. The July Pre-Funded Warrants have an e
Filing Documents
- govx20240904_s1.htm (S-1) — 1830KB
- ex_722005.htm (EX-5.1) — 14KB
- ex_721177.htm (EX-23.1) — 3KB
- ex_721178.htm (EX-FILING FEES) — 20KB
- g01.jpg (GRAPHIC) — 14KB
- g02.jpg (GRAPHIC) — 46KB
- govx20240904_s1img003.jpg (GRAPHIC) — 8KB
- w01.jpg (GRAPHIC) — 3KB
- w02.jpg (GRAPHIC) — 12KB
- w03.jpg (GRAPHIC) — 8KB
- w04.jpg (GRAPHIC) — 3KB
- w05.jpg (GRAPHIC) — 5KB
- wbddecal.jpg (GRAPHIC) — 4KB
- wipflilogo.jpg (GRAPHIC) — 3KB
- 0001437749-24-028640.txt ( ) — 7447KB
- govx-20240630.xsd (EX-101.SCH) — 65KB
- govx-20240630_def.xml (EX-101.DEF) — 467KB
- govx-20240630_lab.xml (EX-101.LAB) — 282KB
- govx-20240630_pre.xml (EX-101.PRE) — 501KB
- govx-20240630_cal.xml (EX-101.CAL) — 58KB
- govx20240904_s1_htm.xml (XML) — 780KB
RISK FACTORS
RISK FACTORS 8 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 19
USE OF PROCEEDS
USE OF PROCEEDS 20 DETERMINATION OF OFFERING PRICE 20 DIVIDEND POLICY 20 CAPITALIZATION 21
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION 40 MANAGEMENT 48
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 51 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 54
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND OFFICERS
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND OFFICERS 56 SELLING STOCKHOLDER 57
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 58 PLAN OF DISTRIBUTION 62 LEGAL MATTERS 63 EXPERTS 63 WHERE YOU CAN FIND MORE INFORMATION 63 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC's website described below under the heading "Where You Can Find More Information." Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. Neither we nor the Selling Stockholder take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. We and the Selling Stockholder are offering to sell, and seeking offers to buy, shares of our Common Stock only in jurisdictions where offers and sales are permitted. You should assume that the information appearing in this prospectus or in any free writing prospectus prepared by us is accurate only as of their respective dates or on the date or dates which are specified in such documents. Our business, financial condition, results of operations and prospects may have changed since those dates. Neither we nor the Selling Stockholder are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for th